{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:48:47Z","timestamp":1793501327650,"version":"4.5.0"},"posted":{"date-parts":[[2025,10,26]]},"group-title":"In Review","reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,23]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\nIn low- and middle-income countries, Alzheimer\u2019s disease and related dementias (ADRD) constitute a growing public health burden. Indeed, the lack of awareness and easy screening tools, such as blood-based biomarkers, leaves many patients undiagnosed. In this study, we explored the core biomarkers of AD in an indigenous African cohort (VALIANT) to assess their relevance and potential utility to aid clinical diagnosis.\nMethods\nNigerian African older adults (n\u2009=\u2009967; \u226550 years) participating in the VALIANT study completed a baseline cross-sectional evaluation with associated clinical diagnosis. We quantified phosphorylated tau (p-tau 217), glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and amyloid beta (A\u03b242 and A\u03b240) levels in plasma with both the Single Molecule Assay (SIMOA, Quanterix) and Nucleic acid-Linked Immuno-Sandwich Assay (NULISA, Alamar) platforms.\nResults\nIn agreement with previous findings, core AD biomarkers were associated with disease severity both in clinical diagnostic and clinico-pathological groups, with stepwise increases of p-tau 217, NfL and GFAP from cognitively unimpaired (CU) to dementia (\n                  <italic>p<\/italic>\n                  \u2009&lt;\u20090.05). These results were consistent across both SIMOA and NULISA platforms. Comparison between sexes showed higher levels of biomarkers in male participants across diagnostic groups. We identified a significant effect of apoE E4 proteotype on p-tau217 levels after adjusting for age and sex but no significant effect on the other AD biomarkers.\nConclusion\nThis first application of cutting-edge plasma AD biomarker immunoassay using two ultrasensitive platforms in an indigenous African cohort showed good concordance and underscores the relevance and utility of blood-based biomarkers of AD in diverse populations. Additionally, sex differences could unveil biological distinctions inherent in the African population.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7688955\/v1","type":"posted-content","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:00:45Z","timestamp":1761562845000},"source":"Crossref","is-referenced-by-count":1,"title":["Blood-based Biomarkers of Alzheimer\u2019s Disease and Neurodegeneration in an Indigenous African Cohort using both SIMOA and NULISA Platforms"],"prefix":"10.21203","author":[{"given":"Tolulope","family":"Akinyemi","sequence":"first","affiliation":[{"name":"Lead City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pola","sequence":"additional","affiliation":[{"name":"University of Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Tan","sequence":"additional","affiliation":[{"name":"University of Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladotun","family":"Olalusi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Yaria","sequence":"additional","affiliation":[{"name":"University College Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ogunde","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Traichel","sequence":"additional","affiliation":[{"name":"University of Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabode","family":"Oguntiloye","sequence":"additional","affiliation":[{"name":"University College Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayotomiwa","family":"Fagbemi","sequence":"additional","affiliation":[{"name":"University College Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eniola","family":"Cadmus","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femi","family":"Popoola","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayowa","family":"Ogunronbi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Olujobi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaoluwa","family":"Famuyiwa","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Akinyemi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick","family":"Pascoal","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayowa","family":"Owolabi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu T. Udeh \u2013","family":"Momoh","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Ladokun","sequence":"additional","affiliation":[{"name":"Lead City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Romero-Ortuno","sequence":"additional","affiliation":[{"name":"Trinity College Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adesola","family":"Ogunniyi","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lawlor","sequence":"additional","affiliation":[{"name":"Trinity College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kalaria","sequence":"additional","affiliation":[{"name":"University of Ibadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"University of Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[{"name":"University of Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufus","family":"Akinyemi","sequence":"additional","affiliation":[{"name":"University of Ibadan, University College Hospital Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","first-page":"e105-e125","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators GBDDF","year":"2022","unstructured":"Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7:e105-e125.","journal-title":"Lancet Public Health"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/alz.12432","article-title":"Dementia in Africa: Current evidence, knowledge gaps, and future directions","volume":"18","author":"Akinyemi RO","year":"2022","unstructured":"Akinyemi RO, Yaria J, Ojagbemi A, et al. Dementia in Africa: Current evidence, knowledge gaps, and future directions. Alzheimers Dement 2022;18:790\u2013809.","journal-title":"Alzheimers Dement"},{"key":"ref3","author":"Kalaria R","year":"2024","unstructured":"Kalaria R, Maestre G, Mahinrad S, et al. The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact. Alzheimers Dement 2024;20:4290\u20134314."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann GM","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263\u2013269.","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR","year":"2018","unstructured":"Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535\u2013562.","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/alz.12618","article-title":"Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature","volume":"18","author":"Zetterberg H","year":"2022","unstructured":"Zetterberg H. Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature. Alzheimers Dement 2022;18:1687\u20131693.","journal-title":"Alzheimers Dement"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.dadm.2019.10.001","article-title":"Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider","volume":"11","author":"Zetterberg H","year":"2019","unstructured":"Zetterberg H, Apostolova LG, Snyder PJ. Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimers Dement (Amst) 2019;11:784\u2013786.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/brain\/awad112","article-title":"The emerging era of staging Alzheimer's disease pathology using plasma biomarkers","volume":"146","author":"Mattsson-Carlgren N","year":"2023","unstructured":"Mattsson-Carlgren N, Palmqvist S. The emerging era of staging Alzheimer's disease pathology using plasma biomarkers. Brain 2023;146:1740\u20131742.","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze S","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain 2023;146:1592\u20131601.","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton NJ","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mila-Aloma M, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 2023;19:1913\u20131924.","journal-title":"Alzheimers Dement"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","article-title":"Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"24","author":"Therriault J","year":"2025","unstructured":"Therriault J, Brum WS, Trudel L, et al. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2025;24:740\u2013752.","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography","volume":"80","author":"Therriault J","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol 2023;80:188\u2013199.","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","volume":"78","author":"Janelidze S","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol 2021;78:149\u2013156.","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet AL","year":"2021","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurol 2021;78:1471\u20131483.","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Alzheimer's Disease Neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease","volume":"74","author":"Mattsson N","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol 2017;74:557\u2013566.","journal-title":"JAMA Neurol"},{"key":"ref16","volume-title":"Neurodegenerative Plasma Biomarkers for Prediction of Hippocampal Atrophy in Older Adults with Suspected Alzheimer's Disease in Kinshasa","author":"Ikanga J","year":"2024","unstructured":"Ikanga J, Jean K, Medina P, et al. Neurodegenerative Plasma Biomarkers for Prediction of Hippocampal Atrophy in Older Adults with Suspected Alzheimer's Disease in Kinshasa, Democratic Republic of Congo. medRxiv 2024."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1477047","DOI":"10.3389\/fnagi.2024.1477047","article-title":"Preliminary reference values for Alzheimer's disease plasma biomarkers in Congolese individuals with and without dementia","volume":"16","author":"Ikanga J","year":"2024","unstructured":"Ikanga J, Jean K, Medina P, et al. Preliminary reference values for Alzheimer's disease plasma biomarkers in Congolese individuals with and without dementia. Front Aging Neurosci 2024;16:1477047.","journal-title":"Front Aging Neurosci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e12496","DOI":"10.1002\/dad2.12496","article-title":"Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo","volume":"15","author":"Ikanga J","year":"2023","unstructured":"Ikanga J, Patel SS, Roberts BR, et al. Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo. Alzheimers Dement (Amst) 2023;15:e12496.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1038\/s41467-024-49859-w","article-title":"Baseline levels and longitudinal changes in plasma Abeta42\/40 among Black and white individuals","volume":"15","author":"Xiong C","year":"2024","unstructured":"Xiong C, Luo J, Wolk DA, et al. Baseline levels and longitudinal changes in plasma Abeta42\/40 among Black and white individuals. Nat Commun 2024;15:5539.","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"100068","DOI":"10.1016\/j.tjfa.2025.100068","article-title":"Correlates of hand grip strength in a cohort of older Nigerian Africans: Findings from the population-based VALIANT project","volume":"14","author":"Akinyemi RO","year":"2025","unstructured":"Akinyemi RO, Olalusi OV, Ogunde GO, et al. Correlates of hand grip strength in a cohort of older Nigerian Africans: Findings from the population-based VALIANT project. J Frailty Aging 2025;14:100068.","journal-title":"J Frailty Aging"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e70669","DOI":"10.1002\/alz.70669","article-title":"Association between cardiovascular and cognitive health among older Indigenous Africans: Data from an urban Nigerian settlement participating in the VALIANT study","volume":"21","author":"Akinyemi RO","year":"2025","unstructured":"Akinyemi RO, Olalusi OV, Ogunde GO, et al. Association between cardiovascular and cognitive health among older Indigenous Africans: Data from an urban Nigerian settlement participating in the VALIANT study. Alzheimers Dement 2025;21:e70669.","journal-title":"Alzheimers Dement"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000518885","article-title":"African Rigorous Innovative Stroke Epidemiological Surveillance: Protocol for a Community-Based Mobile-Health Study","volume":"56","author":"Popoola O","year":"2022","unstructured":"Popoola O, Ovbiagele B, Arulogun O, et al. African Rigorous Innovative Stroke Epidemiological Surveillance: Protocol for a Community-Based Mobile-Health Study. Neuroepidemiology 2022;56:17\u201324.","journal-title":"Neuroepidemiology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e975-e985","DOI":"10.1212\/WNL.0000000000011416","article-title":"Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment","volume":"96","author":"Therriault J","year":"2021","unstructured":"Therriault J, Pascoal TA, Benedet AL, et al. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment. Neurology 2021;96:e975-e985.","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0891988714522695","article-title":"Development and Validation of the Identification and Intervention for Dementia in Elderly Africans (IDEA) Study Dementia Screening Instrument","volume":"27","author":"Gray WK","year":"2014","unstructured":"Gray WK, Paddick SM, Kisoli A, et al. Development and Validation of the Identification and Intervention for Dementia in Elderly Africans (IDEA) Study Dementia Screening Instrument. J Geriatr Psychiatry Neurol 2014;27:110\u2013118.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/gps.4415","article-title":"Community validation of the IDEA study cognitive screen in rural Tanzania","volume":"31","author":"Gray WK","year":"2016","unstructured":"Gray WK, Paddick SM, Collingwood C, et al. Community validation of the IDEA study cognitive screen in rural Tanzania. Int J Geriatr Psychiatry 2016;31:1199\u20131207.","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12877-015-0040-1","article-title":"Validation of the Identification and Intervention for Dementia in Elderly Africans (IDEA) cognitive screen in Nigeria and Tanzania","volume":"15","author":"Paddick SM","year":"2015","unstructured":"Paddick SM, Gray WK, Ogunjimi L, et al. Validation of the Identification and Intervention for Dementia in Elderly Africans (IDEA) cognitive screen in Nigeria and Tanzania. BMC Geriatr 2015;15:53.","journal-title":"BMC Geriatr"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/arclin\/acz086","article-title":"Accuracy of the Montreal Cognitive Assessment in Detecting Mild Cognitive Impairment and Dementia in the Rural African Population","volume":"36","author":"Masika GM","year":"2021","unstructured":"Masika GM, Yu DSF, Li PWC. Accuracy of the Montreal Cognitive Assessment in Detecting Mild Cognitive Impairment and Dementia in the Rural African Population. Arch Clin Neuropsychol 2021;36:371\u2013380.","journal-title":"Arch Clin Neuropsychol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.3402\/gha.v7.25988","article-title":"Development and community-based validation of the IDEA study Instrumental Activities of Daily Living (IDEA-IADL) questionnaire","volume":"7","author":"Collingwood C","year":"2014","unstructured":"Collingwood C, Paddick SM, Kisoli A, et al. Development and community-based validation of the IDEA study Instrumental Activities of Daily Living (IDEA-IADL) questionnaire. Glob Health Action 2014;7:25988.","journal-title":"Glob Health Action"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer RI","year":"1982","unstructured":"Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323\u2013329.","journal-title":"J Gerontol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/bio.2017.0113","article-title":"Biobanking in a Challenging African Environment: Unique Experience from the SIREN Project","volume":"16","author":"Akinyemi RO","year":"2018","unstructured":"Akinyemi RO, Akinwande K, Diala S, et al. Biobanking in a Challenging African Environment: Unique Experience from the SIREN Project. Biopreserv Biobank 2018;16:217\u2013232.","journal-title":"Biopreserv Biobank"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng W","year":"2023","unstructured":"Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun 2023;14:7238.","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton NJ","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol 2024;81:255\u2013263.","journal-title":"JAMA Neurol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"fcaf004","DOI":"10.1093\/braincomms\/fcaf004","article-title":"Identify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay","volume":"7","author":"Wang YT","year":"2025","unstructured":"Wang YT, Ashton NJ, Therriault J, et al. Identify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay. Brain Commun 2025;7:fcaf004.","journal-title":"Brain Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"fcab126","DOI":"10.1093\/braincomms\/fcab126","article-title":"Interactive rather than independent effect of APOE and sex potentiates tau deposition in women","volume":"3","author":"Wang YT","year":"2021","unstructured":"Wang YT, Pascoal TA, Therriault J, et al. Interactive rather than independent effect of APOE and sex potentiates tau deposition in women. Brain Commun 2021;3:fcab126.","journal-title":"Brain Commun"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e14610","DOI":"10.1002\/alz.14610","article-title":"Evaluation of two plasma-based proteotyping assays against APOE epsilon4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies","volume":"21","author":"Dittrich A","year":"2025","unstructured":"Dittrich A, Blennow K, Tan K, et al. Evaluation of two plasma-based proteotyping assays against APOE epsilon4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies. Alzheimers Dement 2025;21:e14610.","journal-title":"Alzheimers Dement"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack CR","year":"2024","unstructured":"Jack CR, Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement 2024;20:5143\u20135169.","journal-title":"Alzheimers Dement"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist S","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020;324:772\u2013781.","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren N","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 2021;13:e14022.","journal-title":"EMBO Mol Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton NJ","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 2021;12:3400.","journal-title":"Nat Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer's Disease","volume":"11","author":"Hansson O","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther 2019;11:34.","journal-title":"Alzheimers Res Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e12168","DOI":"10.1002\/dad2.12168","article-title":"Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration","volume":"13","author":"Ashton NJ","year":"2021","unstructured":"Ashton NJ, Suarez-Calvet M, Karikari TK, et al. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst) 2021;13:e12168.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.dadm.2018.06.001","article-title":"Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles","volume":"10","author":"Keshavan A","year":"2018","unstructured":"Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. Alzheimers Dement (Amst) 2018;10:448\u2013451.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"13872877251364899","DOI":"10.1177\/13872877251364899","article-title":"Exploring the stability of Alzheimer's disease plasma biomarkers stored for extended periods at -20 degrees C: Implications for resource-constrained environments","author":"Ayele BA","year":"2025","unstructured":"Ayele BA, Whitehead PL, Pascual J, et al. Exploring the stability of Alzheimer's disease plasma biomarkers stored for extended periods at -20 degrees C: Implications for resource-constrained environments. J Alzheimers Dis 2025:13872877251364899.","journal-title":"J Alzheimers Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease - the gateway to precision medicine","volume":"14","author":"Ferretti MT","year":"2018","unstructured":"Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol 2018;14:457\u2013469.","journal-title":"Nat Rev Neurol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-025-01684-z","article-title":"Sex differences in the association of Alzheimer's disease biomarkers and cognition in a multicenter memory clinic study","volume":"17","author":"Boccalini C","year":"2025","unstructured":"Boccalini C, Peretti DE, Scheffler M, et al. Sex differences in the association of Alzheimer's disease biomarkers and cognition in a multicenter memory clinic study. Alzheimers Res Ther 2025;17:46.","journal-title":"Alzheimers Res Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/alz.13454","article-title":"Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults","volume":"20","author":"Saloner R","year":"2024","unstructured":"Saloner R, VandeVrede L, Asken BM, et al. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimers Dement 2024;20:376\u2013387.","journal-title":"Alzheimers Dement"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman AM","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement 2021;17:1353\u20131364.","journal-title":"Alzheimers Dement"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities","volume":"18","author":"Syrjanen JA","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement 2022;18:1128\u20131140.","journal-title":"Alzheimers Dement"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e1009977","DOI":"10.1371\/journal.pgen.1009977","article-title":"A locus at 19q13.31 significantly reduces the ApoE epsilon4 risk for Alzheimer's Disease in African Ancestry","volume":"18","author":"Rajabli F","year":"2022","unstructured":"Rajabli F, Beecham GW, Hendrie HC, et al. A locus at 19q13.31 significantly reduces the ApoE epsilon4 risk for Alzheimer's Disease in African Ancestry. PLoS Genet 2022;18:e1009977.","journal-title":"PLoS Genet"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7688955\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7688955\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:09:34Z","timestamp":1764774574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7688955\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":49,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7688955\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,10,26]]},"subtype":"preprint"}}